In Q1 2014, Chinese manufacturers exported artificial joints to EU valuing $20,4 million, which represents 91,06% of total export of artificial joints. EU is the largest buyer of artificial joints produced in China.
There are 22 artificial joint manufacturers in China, located in Jiangsu, Beijing, Shanghai, Shaanxi, Tianjin, Hebei, Fujian and Henan. Belgium is the Nr. 1 target market, who imported $16 million from China. While the YOY export to Germany increased 147.16%.
At the mean time China is also an importer of artificial joints, who imported total value of $36 million of artificial joints from EU in Q1 2014, $35,7 million from USA.
23 May, 2014
Polymer Material Medical Devices Demand Increased in China
The size of Chinese medical device market is expected to reach 340 billion RMB by 2015, moving at a speed of an average yearly compound increasing rate of 23%.
Among tens of thousands of medical devices available in the market, demand to those devices made from polymer material keeps expanding year after year. The polymer material devices designed and manufactured to be small in size, implantable and multipurpose are estimated to be having a yearly increasing rate of 6% until 2018.
Among tens of thousands of medical devices available in the market, demand to those devices made from polymer material keeps expanding year after year. The polymer material devices designed and manufactured to be small in size, implantable and multipurpose are estimated to be having a yearly increasing rate of 6% until 2018.
12 May, 2014
Shanghai Customs Region Imported RMB4.6b Medical Equipment in Q1 2014
In Q1 2014, Shanghai customs region imported medical devices and equipment valuing RMB 4.62 billion, resulting in an increase of 7,8% on YoY basis. Among the total import, RMB 1,7 billion was imported from USA (+6,1%), RMB 1,3 billion from EU (-6,2%), and RMB 0,7 billion from Japan (+6%). Import from USA, EU and Japan represents 81% of total import.
In Chinese hospitals, 100% of artificial hip or knee joints, 100% of pace makers and 90% of CT machines are imported. In Q1 2014, around RMB 0,56 billion of endoscopes were imported to Shanghai customs Region.
In Chinese hospitals, 100% of artificial hip or knee joints, 100% of pace makers and 90% of CT machines are imported. In Q1 2014, around RMB 0,56 billion of endoscopes were imported to Shanghai customs Region.
26 February, 2014
CFDA Exempted 140 Class II Devices from Clinical Trial
China Food and Drug Administration (CFDA) issued notice exempting 140 Class II medical devices from submitting clinical trial when device producers apply for market entry from CFDA. This is already the second batch of clinical trial exemption.
For a Class II device maker outside China, perhaps JV with a local Chinese producer is one the best options if one looks for a long term reward in the Chinese market, depending on the nature of the product itself.
For a Class II device maker outside China, perhaps JV with a local Chinese producer is one the best options if one looks for a long term reward in the Chinese market, depending on the nature of the product itself.
11 February, 2014
New Opportunities in Chinese Health Care Market
On 28 September 2013, the State Council of China issued ‘Several Opinions of the State Council on Speeding up the Development of Healthcare Services’, which was soon brought under the spotlight of the industry.
This document expressed a reform plan which will be guided by the authorities but driven by the market, focusing not only on medical care sector, but also health care sector.
The target of the development of Chinese healthcare services will result in a market size of 8.000 billion RMB with below major targets:
1. Drastic improvement in capability of medical care. This will rely on a balanced system in which the stake holders are non-profit & profit hospitals, public and non-public hospitals, medical treatment, rehabilitation and caring services.
2. Significant improvement in levels of health care management and standards of services. Traditional Chinese health care, caring of aged people, healthcare consultation, sports medical and health care touring services will be encouraged.
3. Improvement in health insurance mechanism. Commercial healthcare insurance should play a more important role in the entire healthcare insurance mechanism.
4. Expansion of supporting clusters of healthcare services. This refers to third party lab centers, third party imaging centers, R & D and manufacturing of (new) drugs, (new) medical and in-vitro devices, rehabilitation devices, healthcare products and fitness equipment.
To achieve the ambitious targets, the government will allow different forms of capitals to enter the market, treat facilities run by private capitals equally to public owned entities. 50%-100% of administrative fees will also be waived by the authorities.
This top-down reform offers tremendous opportunities to huge number of enterprises in the medical & health care industry, especially those prepared early birds.
This document expressed a reform plan which will be guided by the authorities but driven by the market, focusing not only on medical care sector, but also health care sector.
The target of the development of Chinese healthcare services will result in a market size of 8.000 billion RMB with below major targets:
1. Drastic improvement in capability of medical care. This will rely on a balanced system in which the stake holders are non-profit & profit hospitals, public and non-public hospitals, medical treatment, rehabilitation and caring services.
2. Significant improvement in levels of health care management and standards of services. Traditional Chinese health care, caring of aged people, healthcare consultation, sports medical and health care touring services will be encouraged.
3. Improvement in health insurance mechanism. Commercial healthcare insurance should play a more important role in the entire healthcare insurance mechanism.
4. Expansion of supporting clusters of healthcare services. This refers to third party lab centers, third party imaging centers, R & D and manufacturing of (new) drugs, (new) medical and in-vitro devices, rehabilitation devices, healthcare products and fitness equipment.
To achieve the ambitious targets, the government will allow different forms of capitals to enter the market, treat facilities run by private capitals equally to public owned entities. 50%-100% of administrative fees will also be waived by the authorities.
This top-down reform offers tremendous opportunities to huge number of enterprises in the medical & health care industry, especially those prepared early birds.
Subscribe to:
Posts (Atom)